Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind comparison of secukinumab vs ustekinumab in moderate to severe plaque psoriasis
2015-002898-37Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriasis and plaque psoriasis (2 arms), sponsored by Novartis. Primary endpoints: PASI 90 response at week 12 and IGA mod 2011 0/1 at week 12. Started Mar 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2015-002898-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002898-37.